Aspirin May Reduce Ovarian Cancer Risk

Published Online: Wednesday, June 11, 2014
Follow Pharmacy_Times:
Women who take aspirin regularly may be at a reduced risk for ovarian cancer, the results of a meta-analysis suggest. The study, published online on February 6, 2014, in the Journal of the National Cancer Institute, analyzed data from population-based studies to help determine the association between the use of aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, and acetaminophen and the risk of developing ovarian cancer. The results indicated that regular aspirin use was associated with a reduced risk of ovarian cancer. Among 7 studies that reported frequency of use, daily use of aspirin was associated with a 20% decrease in ovarian cancer risk. In 3 studies that included dose information, low-dose aspirin use (less than 100 mg per day) was associated with a 34% reduction in ovarian cancer risk.

Related Articles
While current guidelines indicate dual antiplatelet therapy is appropriate for up to 12 months, the DAPT trial explored how patients could fare up to 30 months.
The FDA is requiring all non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) to include strengthened label warnings describing how the painkillers increase the odds of heart attack or stroke.
Teva has launched a generic version of aspirin and extended-release dipyridamole (Aggrenox) capsules in the United States.
Clinical pharmacists included in team-based interventions can reduce the proportion of potentially inappropriate medications dispensed to elderly patients in the emergency department.
Latest Issues